Arcturus Therapeutics Holdings Inc (NQ:ARCT)

12.07 +0.84 (+7.48%)

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 ↗

August 12, 2021

Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd

Via Benzinga

Arcturus Stock, A Covid Play, Flashes Vital Signs ↗

August 11, 2021

A Relative Strength Rating upgrade for Alcobra shows improving technical performance.

Via Investor's Business Daily

Understanding Arcturus Therapeutics's Unusual Options Activity ↗

August 03, 2021

On Tuesday, shares of Arcturus Therapeutics (NASDAQ:ARCT)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 ↗

August 11, 2021

Upgrades According to Barclays, the prior rating for Albertsons Companies Inc (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 11, 2021

Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The...

Via Benzinga

Arcturus Therapeutics Stock Jumps On mRNA COVID-19 Vaccine Update ↗

August 10, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported a Q2 EPS loss of $(2.07), beating the consensus of $(2.14). The cash balance totaled $433.6 million. After...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

28 Stocks Moving in Tuesday's Pre-Market Session ↗

August 10, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...

Via Benzinga

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

August 09, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge ↗

August 03, 2021

Toward the end of trading Tuesday, the Dow traded up 0.64% to 35,059.40 while the NASDAQ rose 0.34% to 14,731.57. The S&P also rose, gaining 0.65% to 4,415.65. The U.S. has...

Via Benzinga

Topics Stocks

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

88 Biggest Movers From Yesterday ↗

August 05, 2021

Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in...

Via Benzinga

75 Biggest Movers From Yesterday ↗

August 04, 2021

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 03, 2021

Gainers Arcturus Therapeutics (NASDAQ:ARCT) stock moved upwards by 29.05% to $44.73 during Tuesday's regular session. As of 12:35 EST, Arcturus Therapeutics's...

Via Benzinga

Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher ↗

August 03, 2021

Midway through trading Tuesday, the Dow traded up 0.11% to 34,878.06 while the NASDAQ fell 0.37% to 14,626.97. The S&P also fell, dropping 0.01% to 4,386.68. The U.S. has the...

Via Benzinga

Topics Stocks

48 Stocks Moving In Tuesday's Mid-Day Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures...

Via Benzinga

Why Arcturus Therapeutics Stock Is Soaring Today ↗

August 03, 2021

The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.

Via The Motley Fool

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗

August 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

21 Stocks Moving in Tuesday's Pre-Market Session ↗

August 03, 2021

Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 46% to $6.35 in pre-market trading following Form 4 filing from the company’s 10% owner, Retail Ecommerce...

Via Benzinga

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

August 03, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

August 02, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam ↗

August 02, 2021

The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19...

Via Benzinga

Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam ↗

August 02, 2021

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its...

Via Benzinga

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

August 02, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

August 02, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

July 28, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

July 26, 2021

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.